Evidence map›Paper›PMID 41590354›Full record

ReviewCurrent oncology (Toronto, Ont.)2026

MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice-A Narrative Review.

Su Chen Fong, Eddie Lau, David S Liu, Niall C Tebbutt, Richard Khor, Trevor Leong, David Williams, Sergio Uribe, Sweet Ping Ng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Su Chen FongDepartment of Radiation Oncology, Austin Hospital, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-1021-9079
Eddie LauDepartment of Radiology and Molecular Imaging Therapy, Austin Health, Heidelberg, VIC 3084, Australia.
David S LiuUpper Gastrointestinal Surgery Unit, Division of Surgery, Anaesthesia and Procedural Medicine, Austin Health, Heidelberg, VIC 3084, Australia.
Niall C TebbuttDepartment of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia.
Richard KhorDepartment of Radiation Oncology, Austin Hospital, Heidelberg, VIC 3084, Australia.
Trevor LeongDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
David WilliamsDepartment of Pathology, Austin Health, Heidelberg, VIC 3084, Australia.
Sergio UribeDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-4970-9710
Sweet Ping NgDepartment of Radiation Oncology, Austin Hospital, Heidelberg, VIC 3084, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oesophageal cancer remains a significant global health burden with poor survival outcomes despite multimodal treatment. Recent advances in magnetic resonance imaging (MRI) have opened opportunities to improve radiotherapy delivery. This review examines the role of MRI and MR-guided radiotherapy (MRgRT) in oesophageal cancer, focusing on applications in staging, treatment planning, and response assessment, with particular emphasis on magnetic resonance linear accelerator (MR-Linac)-based delivery. Compared to computed tomography (CT), MRI offers superior soft-tissue contrast, enabling more accurate tumour delineation and the potential for reduced treatment margins. Real-time MR imaging during treatment can facilitate motion management, while daily adaptive planning can accommodate anatomical changes throughout the treatment course. Functional MRI sequences, including diffusion-weighted and dynamic contrast-enhanced imaging, offer quantitative data for treatment response monitoring. Early clinical and dosimetric studies demonstrate that MRgRT can significantly reduce radiation dose to critical organs while maintaining target coverage. However, clinical evidence for MRgRT in oesophageal cancer is limited to small early-phase studies, with no phase II/III trials demonstrating improvements in survival, toxicity, or patient-reported outcomes. Long-term clinical benefits and cost-effectiveness remain unproven, highlighting the need for prospective outcome-focused studies to define the role for MRgRT within multimodality treatment pathways.

Indexed as

Esophageal NeoplasmsMagnetic Resonance ImagingRadiotherapy, Image-GuidedHumansadaptive radiotherapydiffusion-weighted imagingfunctional MRImotion managementMR-guided radiotherapyMR-Linacoesophageal cancerpersonalised radiotherapytumour delineation

Identifiers

PMID41590354
PMCPMC12839635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.